IIIA/B期非小细胞肺癌治疗前代谢肿瘤体积揭示根治性放化疗方案疗效差异:ESPATUE随机III期试验分析
该分析纳入ESPATUE随机III期试验中接受PET/CT分期的169例IIIA/IIIB期非小细胞肺癌患者,评估治疗前代谢肿瘤体积(MTV)对根治性放化疗(RCT)后生存的预后价值。结果显示MTV作为连续变量与生存无显著关联(p>0.5),高MTV(>95.4 ml)与低MTV患者5年生存率分别为33%和32%,MTV每增加10 ml的风险比为0.997(95%CI 0.973-1.022),且MTV斜率显著低于ACRIN 6668/RTOG 0235试验(p=0.002)。结论不支持根据MTV进行治疗个体化。
要点
- MTV连续变量与根治性RCT后生存无显著关联(p>0.5)。
- 高MTV(>95.4 ml)与低MTV患者5年生存率分别为33%和32%。
- MTV每增加10 ml风险比0.997(95%CI 0.973-1.022)。
核心结论
- 在ESPATUE试验中,MTV大的IIIA/IIIB期NSCLC患者接受根治性RCT生存特别好。
- 本研究不支持根据MTV进行治疗个体化。
- ESPATUE与ACRIN试验差异在于含顺铂诱导化疗和强化放疗方案,后者对MTV大的患者特别有效。
研究设计与样本
- 分析德国ESPATUE随机III期试验中接受PET/CT分期的患者。
- ESPATUE比较诱导化疗和RCT后根治性RCT(A组)与手术(B组),可切除IIIA/IIIB期NSCLC患者随机分配。
- MTV采用固定阈值法和基于模型的迭代体积阈值法测量,用比例风险模型和Kaplan-Meier生存函数分析。
主要发现
- MTV作为连续变量在117例计划根治性RCT患者和全部169例接受治疗前PET/CT患者中均未显示生存差异(p>0.5)。
- 计划根治性RCT患者中,高MTV(>95.4 ml)5年生存率33%(95%CI 17-49%),低MTV为32%(95%CI 22-42%)。
- MTV每增加10 ml的生存风险比为0.997(95%CI 0.973-1.022),斜率显著低于ACRIN 6668/RTOG 0235试验(随机效应模型,p=0.002)。
- ACRIN与ESPATUE试验的MTV大小分布无差异(p=0.97)。
临床怎么用
- 治疗前MTV不应单独用于III期NSCLC根治性RCT的治疗个体化决策。
- 含顺铂诱导化疗和强化放疗方案可能对MTV大的患者特别有效。
局限性
- 分析基于ESPATUE试验的特定人群和方案,结果外推需谨慎。
- MTV测量采用固定阈值和模型迭代阈值法,未提及其他方法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: According to the ACRIN 6668/RTOG 0235 trial, pretreatment metabolic tumour volume (MTV) as detected by 18F-fluorodeoxyglucose PET/CT is a prognostic factor in patients with stage III non-small-cell lung cancer (NSCLC) after definitive radiochemotherapy (RCT). To validate the prognostic value of MTV in patients with stage III NSCLC after RCT, we analysed mature survival data from the German phase III trial ESPATUE. METHODS: This analysis included patients who were staged by PET/CT and who were enrolled in the ESPATUE trial, a randomized study comparing definitive RCT (arm A) with surgery (arm B) after induction chemotherapy and RCT in patients with resectable stage IIIA/IIIB NSCLC. Patients refusing surgery and those with nonresectable disease were scheduled to receive definitive RCT. MTV was measured using a fixed threshold-based approach and a model-based iterative volume thresholding approach. Data were analysed using proportional hazards models and Kaplan-Meier survival functions. RESULTS: MTV as a continuous variable did not reveal differences in survival between the 117 patients scheduled to receive definitive RCT and all 169 enrolled patients who underwent pretreatment PET/CT (p > 0.5). Five-year survival rates were 33% (95% CI 17-49%) in patients scheduled for definitive RCT with a high MTV (>95.4 ml) and 32% (95% CI: 22-42%) in those with a low MTV. The hazard ratio for survival was 0.997 (95% CI 0.973-1.022) per 10-ml increase in MTV and the slope was significantly shallower than that in the ACRIN 6668/RTOG 0235 trial (random effects model, p = 0.002). There were no differences in MTV size distributions between the ACRIN and ESPATUE trials (p = 0.97). CONCLUSION: Patients with stage III NSCLC and a large MTV in whom definitive RCT had a particularly good survival in the ESPATUE trial. Treatment individualization according to MTV is not supported by this study. The ESPATUE and ACRIN trials differed by the use of cisplatin-containing induction chemotherapy and an intensified radiotherapy regimen that were particularly effective in patients with large MTV disease.
引用
- Guberina M, Eberhardt W, Stuschke M, et al. Pretreatment metabolic tumour volume in stage IIIA/B non-small-cell lung cancer uncovers differences in effectiveness of definitive radiochemotherapy schedules: analysis of the ESPATUE randomized phase 3 trial. Eur J Nucl Med Mol Imaging. 2019. PMID: 30710323. doi:10.1007/s00259-019-4270-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。